- Notification that Annual Report will be submitted late (NT 10-K)
01 Octobre 2012 - 2:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One):
|
T
Form 10-KSB
£
Form 20-F
£
Form 11-K
£
Form 10-QSB
£
Form
N-SAR
|
|
|
|
For Period Ended: June 30, 2012
|
|
|
|
£
Transition Report on Form 10-K
|
|
£
Transition Report on Form 20-F
|
|
£
Transition Report on Form 11-K
|
|
£
Transition Report on Form 10-Q
|
|
£
Transition Report on Form N-SAR
|
|
|
|
For the Transition Period Ended: ________________________
|
Read Instruction (on back page)
Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:
PART I -- REGISTRANT INFORMATION
Healthient, Inc.
Full Name of Registrant
N/A
Former Name if Applicable
15132 Park of Commerce Blvd., 2nd Floor
Address of Principal Executive Office (Street and Number)
Florida 33478
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(Check box if appropriate.)
£
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
T
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed -- due date; or the subject quarterly report of transition report on Form 10-QSB, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
£
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III -- NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K,
10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Registrant is in the process of compiling the financial information
for the year ended June 30, 2012 for the Form 10-K, all of which information has not yet been received and processed.
PART IV -- OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
Katherine T. West,
President and CEO
|
|
(888)
|
|
720-2112
|
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
|
|
|
|
S
Yes
£
No
|
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
|
|
£
Yes
S
No
|
|
|
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
Healthient, Inc.
(Name of Registrant as Specified in Charter
has caused this notification to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date: September 28, 2012
|
By:
|
/s/ Katherine T. West
|
|
|
|
INSTRUCTION; The form may be signed by an executive officer
of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed
or printed beneath the signature. if the statement is signed on behalf of the registrant by an authorized representative (other
than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with
the form.
Curative Biosciences (CE) (USOTC:CBDX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Curative Biosciences (CE) (USOTC:CBDX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024